Online citations, reference lists, and bibliographies.
← Back to Search

Application Of Nanotechnology In Cancer Therapy And Imaging

X. Wang, Lily L. Yang, Z. Chen, D. M. Shin
Published 2008 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Recent developments in nanotechnology have provided researchers with new tools for cancer imaging and treatment. This technology has enabled the development of nanoscale devices that can be conjugated with several functional molecules simultaneously, including tumor‐specific ligands, antibodies, anticancer drugs, and imaging probes. Since these nanodevices are 100 to 1,000‐fold smaller than cancer cells, they can be easily transferred through leaky blood vessels and interact with targeted tumor‐specific proteins both on the surface of and inside cancer cells. Therefore, their application as cancer cell‐specific delivery vehicles will be a significant addition to the currently available armory for cancer therapeutics and imaging.
This paper references
10.1200/JCO.1997.15.2.653
Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
D. Northfelt (1997)
Albumin-bound nanoparticle paclitaxel.
W. Gradishar (2005)
Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Sandy Ni (2002)
10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C
HPMA copolymer–anticancer drug–OV‐TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro
V. Omelyanenko (1998)
10.1002/j.1552-4604.1996.tb04152.x
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
10.1248/BPB.29.1790
Nanocarriers: promising vehicle for bioactive drugs.
M. Rawat (2006)
10.1016/J.ATHORACSUR.2004.06.055
Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots.
E. Soltesz (2005)
10.1309/5CWPU41AFR1VYM3F
Targeted therapies for cancer 2004.
J. Ross (2004)
10.1016/S0163-7827(03)00033-X
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.
S. Moghimi (2003)
Liposomes designed to avoid the reticuloendothelial system.
D. Papahadjopoulos (1990)
10.1038/nbt1006-1211
The emerging nanomedicine landscape
Volker Wagner (2006)
10.1016/S0959-8049(03)00273-9
Exploiting the hallmarks of cancer: the future conquest of breast cancer.
G. Sledge (2003)
10.1021/BC000080W
Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers.
Z. Lu (2001)
10.1023/A:1011199028318
Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer.
K. Harrington (2001)
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
O. Soepenberg (2005)
10.1158/1078-0432.CCR-03-0041
Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments
P. Sapra (2004)
10.1016/J.PHARMTHERA.2006.10.003
How can we best use structural information on P-glycoprotein to design inhibitors?
C. A. McDevitt (2007)
10.1021/BC000079X
Improvement of MRI probes to allow efficient detection of gene expression.
D. Högemann (2000)
10.1007/s00280-006-0397-0
Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
M. Campone (2006)
Drug delivery systems: enter ing the mainstream
TM Allen (2004)
10.1002/JMRI.1880070629
Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages
A. Moore (1997)
10.4049/jimmunol.169.1.476
Neutrophil Transepithelial Migration: Evidence for Sequential, Contact-Dependent Signaling Events and Enhanced Paracellular Permeability Independent of Transjunctional Migration1
H. Edens (2002)
10.1016/S0378-5173(99)00447-0
Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system.
U. Gaur (2000)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
10.1007/s00280-006-0235-4
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer
T. Dragovich (2006)
10.1126/SCIENCE.7434025
pH-sensitive liposomes: possible clinical implications.
M. Yatvin (1980)
In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors.
M. Kircher (2003)
10.1016/S0304-4165(01)00142-8
Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology.
P. Laverman (2001)
10.1038/sj.onc.1207463
Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity
V. Guillemard (2004)
10.1162/1535350042973481
Near-infrared optical imaging of integrin αvβ3 in human tumor xenografts
W. Wang (2004)
10.1038/bjc.1996.625
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
D. Goren (1996)
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
G. Kong (2000)
10.1007/s11060-006-9195-0
Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme
K. Maier-Hauff (2006)
10.3109/10611869608996827
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro.
V. Omelyanenko (1996)
10.1126/SCIENCE.281.5385.2016
Quantum dot bioconjugates for ultrasensitive nonisotopic detection.
W. C. Chan (1998)
10.1021/NL052405T
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects.
W. Cai (2006)
10.1016/J.IJPHARM.2004.05.025
Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo.
H. Hatakeyama (2004)
10.1006/CYTO.2000.0769
Biopharmaceutics of liposomal interleukin 2, oncolipin.
M. Neville (2000)
10.1158/1078-0432.CCR-03-0315
A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors
J. Rademaker-Lakhai (2004)
10.1016/0165-6147(94)90314-X
Long-circulating (sterically stabilized) liposomes for targeted drug delivery.
T. Allen (1994)
10.1186/bcr432
Liposome-based drug delivery in breast cancer treatment
J. Park (2002)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
A Phase 2 trial of the liposomal DACH platinum LNDDP in patients with therapy-refractory advanced colorectal cancer
T Dragovich (2006)
10.1158/1078-0432.CCR-06-0946
Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors
G. R. Reddy (2006)
10.1126/science.1125949
Molecular Imaging in Cancer
R. Weissleder (2006)
10.1200/JCO.2006.06.6159
New technologies and directed agents for applications of cancer imaging.
M. Atri (2006)
10.1007/BF00047468
Transport of molecules across tumor vasculature
R. Jain (2004)
10.1016/S0092-8674(00)81683-9
The Hallmarks of Cancer
D. Hanahan (2000)
10.1016/J.ADDR.2004.02.014
Nanoparticle and targeted systems for cancer therapy.
L. Brannon-Peppas (2004)
10.3816/CLC.2006.N.027
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
K. Albain (2006)
10.1364/BIO.2006.SF3
Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy.
Y. Koo (2007)
10.1517/14728222.8.4.335
Development of ligand-targeted liposomes for cancer therapy
C. Noble (2004)
10.1158/0008-5472.CAN-03-0654
Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes
R. E. Eliaz (2004)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1038/sj.bjc.6602204
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Y. Matsumura (2004)
10.1038/nm0996-979
Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library
R. Begent (1996)
10.1117/12.591181
Quantum dot-based multiplexed fluorescence resonance energy transfer.
A. R. Clapp (2005)
Phase I and pharmacokinetic study of DE310 in patients with advanced solid tumors
O Soepenberg (2005)
10.1007/s10637-007-9040-0
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers
T. Ciuleanu (2007)
10.1007/s10555-006-7886-9
Matrix metalloproteinases and tumor metastasis
E. Deryugina (2006)
10.1517/14656566.7.8.1041
Albumin-bound paclitaxel: a next-generation taxane
W. Gradishar (2006)
10.1593/NEO.05769
Nanoparticle imaging of integrins on tumor cells.
X. Montet (2006)
10.1016/S0169-409X(02)00180-1
Effective drug delivery by PEGylated drug conjugates.
R. Greenwald (2003)
10.1038/sj.bjc.6603345
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer
S. White (2006)
Near-infrared optical imaging of proteases in cancer.
U. Mahmood (2003)
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
P. Vasey (1999)
10.1002/cncr.22035
Emerging implications of nanotechnology on cancer diagnostics and therapeutics
A. Cuenca (2006)
10.1007/978-1-4020-5133-3_21
Molecular imaging of cancer using PET and SPECT.
A. Kjaer (2006)
10.2174/1568009043332989
Novel approaches for targeted cancer therapy.
V. Guillemard (2004)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1038/sj.bjc.6601811
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
F. M. Wachters (2004)
10.2165/00003088-199121030-00001
Liposomal Drug Delivery
R. Fielding (1991)
10.1126/SCIENCE.8128245
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
[Micelle carrier system in clinical trial].
Y. Matsumura (2006)
10.1038/nrc1566
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization.
E. Batrakova (2001)
10.1021/NL061412U
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems.
N. Nasongkla (2006)
10.1021/BC990092L
Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin.
M. Pechar (2000)
10.1038/sj.bjc.6601922
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D. Bissett (2004)
Magnetic resonance molecular imaging of the HER-2/neu receptor.
D. Artemov (2003)
10.1007/s00280-007-0509-5
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
A. Clamp (2007)
10.1016/0959-8049(96)00091-3
Clinical trials of P-glycoprotein reversal in solid tumours.
D. Ferry (1996)
10.1016/J.JCONREL.2005.09.034
Block copolymer micelles: preparation, characterization and application in drug delivery.
G. Gaucher (2005)
10.1016/J.JCONREL.2004.12.018
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
E. Lee (2005)
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
P. Vasey (1999)
10.1517/17425247.3.3.311
Nanoparticle–aptamer bioconjugates for cancer targeting
O. Farokhzad (2006)
10.1016/J.TIBTECH.2005.11.006
Polymer conjugates: nanosized medicines for treating cancer.
M. Vicent (2006)
10.1038/sj.bjc.6690657
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
A. Thomson (1999)
10.1006/MVRE.1996.0041
Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity.
P. A. Netti (1996)
10.1002/JMRI.1880040508
Contrast‐enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide
B. Hamm (1994)
10.2174/156720105774370159
Ligand-targeted liposomes for cancer treatment.
P. Sapra (2005)
10.1016/S0169-409X(99)00062-9
Targeted drug delivery via the folate receptor.
J. Sudimack (2000)
10.1038/sj.onc.1209597
Glycolysis inhibition for anticancer treatment
H. Pelicano (2006)
Technology evaluation: PK1, Pfizer/Cancer Research UK.
V. Bilim (2003)
10.1016/S0168-3659(99)00245-X
Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents.
M. Liu (2000)
10.1016/J.BIOMATERIALS.2006.10.002
In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications.
Yong Woo Cho (2007)
Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
M. Sugano (2000)
10.3816/CLC.2005.N.039
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
D. Richards (2005)
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase
AM Mansour (2003)
10.1002/mrm.10406
MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles
D. Artemov (2003)
10.1038/NMAT1390
Quantum dot bioconjugates for imaging, labelling and sensing
Igor L. Medintz (2005)
Breast MRI and 18F FDG PET/CT in the management of breast cancer.
A. Iagaru (2007)
10.1007/s00280-004-0911-1
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951
Y. Ochi (2004)
10.1016/S1046-5928(02)00546-6
Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery.
M. Backer (2002)
10.1016/J.ACRA.2004.04.018
Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery.
H. Choi (2004)
10.1038/nm1467
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging
Jaehyun Lee (2007)
10.1007/s00280-003-0685-x
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma
N. Sarapa (2003)
10.1038/modpathol.3800628
Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots
Thomas J. Fountaine (2006)
10.1097/00001813-200104000-00003
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
J. M. Meerum Terwogt (2001)
10.1007/BF00874153
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)
S. Danhauser-Riedl (2004)
10.1016/J.IJPHARM.2007.03.039
UEA I-bearing nanoparticles for brain delivery following intranasal administration.
X. Gao (2007)
10.1023/B:BMMD.0000031747.05317.81
Molecular Imaging Applications in Nanomedicine
K. C. Li (2004)
10.1038/74464
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells
M. Lewin (2000)
10.1080/10611860400011869
Antibody-targeted Polymer–doxorubicin Conjugates with pH-controlled Activation
K. Ulbrich (2004)
10.1093/ANNONC/MDH092
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Y. Matsumura (2004)
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOXOXD)
S Danhauser-Riedl (1993)
10.1002/mrm.10068
Detection of lymph node metastases by contrast‐enhanced MRI in an experimental model
P. Wunderbaldinger (2002)
10.1002/NBM.924
Iron oxide MR contrast agents for molecular and cellular imaging
J. Bulte (2004)
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Ahmed M. Mansour (2003)
10.1021/MP050032Z
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention.
S. Sahoo (2005)
10.1111/j.1349-7006.2004.tb02495.x
Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts
T. Hamaguchi (2004)
10.1038/nm1486
In vivo imaging of siRNA delivery and silencing in tumors
Z. Medarova (2007)
10.1016/J.BBAMEM.2004.03.006
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
G. Charrois (2004)
Oncotic pressure in solid tumors is elevated.
M. Stohrer (2000)
Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
A. Pal (2005)
10.1200/JCO.2003.03.143
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
E. Rowinsky (2003)
10.1023/A:1016201732368
A Phase I Study of SPI-077 (Stealth® Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer
D. Rosenthal (2004)
10.1056/NEJMOA022749
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
M. Harisinghani (2003)
10.1016/J.ADDR.2004.01.011
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
A. Gabizon (2004)
10.1080/10428190500052438
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia
A. Fassas (2005)
10.1016/J.YGYNO.2003.12.037
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
M. Seiden (2004)
Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts.
W. Wang (2004)
10.1007/S12094-006-0062-4
Contributions of advanced proteomics technologies to cancer diagnosis
S. Ciordia (2006)
Gateways to clinical trials.
M. Bayes (2005)
10.1016/S1368-7646(03)00082-7
Liposome-based approaches to overcome anticancer drug resistance.
C. Mamot (2003)
10.1148/RADIOLOGY.214.2.R00FE19568
Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model.
A. Moore (2000)
10.1038/nbt994
In vivo cancer targeting and imaging with semiconductor quantum dots
X. Gao (2004)
10.1038/NMAT1775
FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents
W. Seo (2006)
10.1677/ERC.1.01045
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
R. Duncan (2005)
10.1016/S1476-5586(03)80050-7
Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy.
Eyk A. Schellenberger (2003)
10.1016/J.JPBA.2006.10.034
Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.
Y. Shiose (2007)
10.1200/JCO.20.6.1668
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
L. Seymour (2002)
10.1021/BC0155770
Molecular vehicles for targeted drug delivery.
M. Backer (2002)
10.2174/1381612043383467
Targeted liposomal drug delivery in cancer.
O. Medina (2004)
10.1038/nrd1088
The dawning era of polymer therapeutics
R. Duncan (2003)
10.1021/MP0500014
Iron oxide nanoparticles for sustained delivery of anticancer agents.
Tapan Jain (2005)
10.1038/nrc882
Molecular imaging of cancer with positron emission tomography
S. Gambhir (2002)
10.1054/bjoc.2001.2165
Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
E. Batrakova (2001)
10.1097/01.CAD.0000167902.53039.5A
Liposomal encapsulated anti-cancer drugs.
R. Hofheinz (2005)
10.1097/01.coc.0000224494.07907.4e
Paclitaxel Poliglumex (PPX-Xyotax) and Concurrent Radiation for Esophageal and Gastric Cancer: A Phase I Study
T. Dipetrillo (2006)
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
P. Sapra (2002)
10.1038/nrc903
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
10.1016/J.COPBIO.2004.11.003
In vivo molecular and cellular imaging with quantum dots.
X. Gao (2005)
10.1016/J.AB.2004.09.046
Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study.
W. Guo (2005)
10.1016/S0730-725X(96)00335-9
Crystal size and properties of superparamagnetic iron oxide (SPIO) particles.
C. Sjögren (1997)
10.1038/nbt876
Small-scale systems for in vivo drug delivery
David A. LaVan (2003)
10.1023/A:1022482604276
Blood-Brain Barrier Carrier-Mediated Transport and Brain Metabolism of Amino Acids
W. Pardridge (2004)
10.1201/b14213-15
Diagnostics and Therapeutics
Lois N. Magner (2005)
10.1097/01.NAN.0000264712.26219.67
Liposomal drug delivery.
Allison Sd (2007)
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
S. C. van der Schoot (2006)
10.1158/1078-0432.CCR-05-0803
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
A. Boddy (2005)
Emerging implications of nanotechnology on
AG Cuenca
10.1016/S0378-4347(97)00362-9
On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level.
X. Pépin (1997)
10.1081/LPR-120004770
THE NEXT GENERATION OF LIPOSOME DELIVERY SYSTEMS: RECENT EXPERIENCE WITH TUMOR-TARGETED, STERICALLY-STABILIZED IMMUNOLIPOSOMES AND ACTIVE-LOADING GRADIENTS
R. Abra (2002)
10.1016/S0169-409X(02)00045-5
Poly(L-glutamic acid)--anticancer drug conjugates.
Chun Xing Li (2002)



This paper is referenced by
10.1098/rsif.2009.0243
Optical imaging-guided cancer therapy with fluorescent nanoparticles
S. Jiang (2009)
10.1016/j.colsurfb.2012.02.024
Elaboration and characterization of nanoliposome made of soya; rapeseed and salmon lecithins: application to cell culture.
Elmira Arab Tehrany (2012)
10.1016/j.biomaterials.2014.02.010
The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin.
Shuai Shi (2014)
10.1007/s13277-015-3706-6
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy
B. Bahrami (2015)
10.1038/s41598-019-45332-7
An Improved Method for Fabrication of Ag-GO Nanocomposite with Controlled Anti-Cancer and Anti-bacterial Behavior; A Comparative Study
S. Khorrami (2019)
10.1016/J.MENCOM.2019.01.009
Synthetic asymmetric lipid-like organosilanes for liposomal nanohybrid cerasomes toward potential medical applications
Zaret G. Denieva (2019)
10.1016/j.biomaterials.2010.12.055
Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles.
Y. Tan (2011)
10.4236/jct.2011.23045
Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail
V. V. Prabhu (2011)
10.1002/iub.485
Delivery of nanoparticle‐complexed drugs across the vascular endothelial barrier via caveolae
Zhenjia Wang (2011)
10.1007/s40011-012-0080-7
Drug Delivery Using Nanocarriers: Indian Perspective
S. Gupta (2012)
Nanotechnology in the field of clinical oncology Klinik onkoloji alanında nanoteknoloji
M. Topçul ()
10.1016/j.cbi.2014.05.013
Intracellular transport of nanodiamond particles in human endothelial and epithelial cells.
K. Solarska-Ściuk (2014)
10.3322/caac.21199
Nanooncology: The future of cancer diagnosis and therapy
A. Thakor (2013)
10.2147/OTT.S62057
Cerium oxide nanoparticles in cancer
Y. Gao (2014)
10.4028/www.scientific.net/JNanoR.58.1
Anti Wnt-1 Monoclonal Antibody’s Conjugated with Gold Nanoparticles, Induced Apoptosis on MCF-7 Breast Cancer Cell Lines
Mehdi Tayybi Azar (2019)
10.1109/NANO.2010.5698025
Inductively coupled RF heating of nano-particle for non-invasive and selective cancer cell destruction
Hyo-Chang Lee (2010)
10.1016/j.biomaterials.2010.08.053
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Y. Liu (2010)
10.1016/S1995-7645(12)60193-X
Antiproliferative effect of silver nanoparticles synthesized using amla on Hep2 cell line.
F. S. Rosarin (2013)
10.1016/B978-0-323-46144-3.00027-1
Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach
F. G. Praça (2017)
10.1007/s11172-017-1973-7
Folic acid and its derivatives for targeted photodynamic therapy of cancer
Nikita V. Suvorov (2017)
10.2147/IJN.S175340
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
S. Xu (2019)
Importan ce of Solid L ipid Nanoparti
(2011)
10.3892/ijo.2014.2604
Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study.
V. Lorusso (2014)
10.1002/PAT.3731
Synthesis of a new nanoparticle system based on electrostatic alginate‐piperazine interactions
J. M. Román (2016)
10.1016/S1470-2045(10)70196-0
Cyanine dyes in optical imaging of tumours.
Chunmeng Shi (2010)
10.5681/apb.2014.074
Biodegradable m-PEG/PCL Core-Shell Micelles: Preparation and Characterization as a Sustained Release Formulation for Curcumin.
H. Danafar (2014)
10.1002/ADFM.201001435
Polyhedral Oligomeric Silsesquioxanes-Containing Conjugated Polymer Loaded PLGA Nanoparticles with Trastuzumab (Herceptin) Functionalization for HER2-Positive Cancer Cell Detection
K. Li (2011)
10.1021/nn101762b
Plugging into proteins: poisoning protein function by a hydrophobic nanoparticle.
Guanghong Zuo (2010)
10.1111/bju.12782
Nanotechnology applications in urology: a review
M. Maddox (2014)
10.1016/j.biomaterials.2010.02.074
The cytotoxicity of CdTe quantum dots and the relative contributions from released cadmium ions and nanoparticle properties.
Yuanyuan Su (2010)
10.1039/C0JM04115G
Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy
Ting-ting Wang (2011)
10.1007/978-1-4614-2305-8_9
Polymer-Modified Nanoparticles as Targeted MR Imaging Agents
Stephen G. Boyes (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar